The ESR1-mutated metastatic breast cancer market is projected to grow at 9.6% CAGR through 2036, driven by rising prevalence of endocrine-resistant HR-positive/HER2-negative breast cancer and adoption of precision oncology. Novel oral SERDs and targeted agents from major pharmaceutical companies are reshaping the treatment landscape. The market was valued at USD 1.5 billion in 2025, with the US representing the largest market share. Recent FDA approvals include VEPPANU (vepdegestrant), the first PROTAC therapy, while several emerging therapies are in clinical development.

Rigel Pharmaceuticals announced an exclusive global licensing agreement with Arvinas and Pfizer for VEPPANU (vepdegestrant), an oral PROTAC drug for ER+/HER2- ESR1-mutated advanced or metastatic breast cancer. Rigel will contribute up to $40 million toward development over four years and pursue U.S. and global commercialization rights. The drug received FDA approval in May 2026, showing a 43% reduction in disease progression or death risk compared to fulvestrant in the Phase 3 VERITAC-2 trial.

Arvinas, Inc. announced FDA approval of VEPPANU (vepdegestrant), the first-and-only FDA-approved PROTAC protein degrader, for treating estrogen receptor-positive advanced breast cancer with ESR1 mutations. The approval came ahead of the FDA-assigned PDUFA date of June 5, 2026. The company also reported positive Phase 1 data for ARV-102 showing greater than 50% LRRK2 degradation in Parkinson's disease patients.

The FDA approved VEPPANU (vepdegestrant), a first-of-its-kind PROTAC therapy developed by Pfizer and Arvinas for treating advanced breast cancer with ESR1 mutations. The Phase 3 VERITAC-2 trial showed vepdegestrant reduced disease progression risk by 43% compared to fulvestrant, with median PFS of 5 months versus 2.1 months. Guardant Health's Guardant360 CDx was also approved as a companion diagnostic for patient identification.

Arvinas and Pfizer announced FDA approval of VEPPANU (vepdegestrant), the first-ever approved PROTAC protein degrader, for treating ESR1-mutated ER+/HER2- advanced breast cancer. The approval was granted ahead of schedule, based on Phase 3 VERITAC-2 trial data showing vepdegestrant reduced disease progression risk by 43% compared to fulvestrant. The companies plan to select a third-party partner for commercialization.

Arvinas announced it will present Phase 1 clinical trial data for ARV-102, a PROTAC degrader targeting LRRK2, at the AD/PD 2026 conference in Copenhagen on March 18, 2026. The presentation will highlight safety, pharmacokinetic, and pharmacodynamic data from participants with Parkinson's disease. The company plans to initiate a Phase 1b trial in progressive supranuclear palsy patients in the first half of 2026, pending regulatory approval.

Researchers at University of Technology Sydney have developed nanoparticle-mediated targeting chimeras (NPTACs), a new technology that can degrade disease-causing proteins to treat conditions like dementia, brain cancer, and autoimmune disorders. The technology overcomes limitations of conventional targeted protein degradation tools and has shown strong preclinical results. The targeted protein degradation market is expected to exceed $10 billion USD by 2030.

Arvinas presented preclinical data showing enhanced antitumor activity when combining ARV-393 and glofitamab in a high-grade B-cell lymphoma model, with plans to initiate a Phase 1 clinical trial combination cohort in 2026.

Arvinas will present multiple research abstracts about vepdegestrant, an investigational drug for estrogen receptor positive breast cancer, at the San Antonio Breast Cancer Symposium in December 2025. The drug is being co-developed with Pfizer and is currently under FDA review.

Arvinas will present preclinical data for ARV-393, a PROTAC BCL6 degrader targeting non-Hodgkin lymphoma, at the 2025 ASH Annual Meeting in Orlando, Florida.

Arvinas presented promising preclinical data for ARV-806, a targeted protein degradation drug designed to address KRAS G12D mutations in cancers like pancreatic, colorectal, and lung cancer, demonstrating robust protein degradation and potential therapeutic benefits.

Arvinas will present preclinical data for ARV-806, a novel PROTAC degrader targeting mutant KRAS G12D, at the 2025 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics in Boston.